CGTLive®’s Weekly Rewind – October 11, 2024

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

2. Daniela van Eickels, MD, PhD, MPH, on Addressing Unmet Needs in Autoimmune Disease With Cell Therapy

The vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization discussed the Autoimmunity Cell Therapy Network.

3. Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study

The ORR in the enhanced lymphodepletion arm was 100% in patients who had not previously received an antiBCMA therapy.

4. Paul Melmeyer, MPP, on the Importance of Gene Therapy for MDA’s Upcoming 2025 Conference

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the growing interest in gene therapy for attendees of the annual meeting.

5. Kiromic BioPharma’s NSCLC T-cell Therapy Deltacel Continues to Provide Disease Stabilization in Updated Data

Kiromic reported that the fourth patient to have been treated in the trial showed a 5.3% reduction in tumor size with regard to baseline.